Atamyo Therapeutics
Executivos
Veja o organograma con seus 7 executivos principais
Biografias mais buscadas da Atamyo Therapeutics
Criar um alerta
para seguir os movimentos de executivos da Atamyo Therapeutics.
Biotecnologia
Atamyo Therapeutics possui 2.282 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Endeavor BioMedicines acaba de anunciar uma arrecadação de fundos de 132 milhões de dólares. (publicado em 25 de abril de 2024).
- Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Atamyo Therapeutics
- Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5 - Atamyo Therapeutics
- 2024 - Atamyo Therapeutics
- Atamyo Therapeutics obtient les autorisations réglementaires en Europe pour lancer l’essai clinique de ATA-200, sa thérapie génique pour traiter la myopathie des ceintures LGMD-2C/R5 - Atamyo Therapeutics
- First clinical results of ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), presented at ESGCT - Atamyo Therapeutics
- Premiers résultats cliniques d'ATA-100, une thérapie génique pour le traitement de la dystrophie musculaire des ceintures de type 2I/R9 (LGMD 2I/R9), présentés au congrès ESGCT - Atamyo Therapeutics
- Atamyo Therapeutics annonce sa participation à plusieurs conférences et des communications scientifiques clés sur ses programmes LGMD - Atamyo Therapeutics
- Atamyo Therapeutics Announces participations in Conferences and Key Scientific Communications on its LGMD programs - Atamyo Therapeutics
- ATA-200, Atamyo Therapeutics’ Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5, reaches key milestones with the filing of a clinical trial application in Europe and a non-dilutive financing from France 2030 program - Atamyo Therapeutics
- ATA-200, thérapie génique développée par Atamyo et destinée au traitement de la dystrophie musculaire des ceintures de type 2C/R5, franchit des étapes clés avec le dépôt d’une demande d’essai clinique en Europe et un financement non-dilutif du programme F
- IND for ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), cleared to proceed by FDA - Atamyo Therapeutics
- View more press releases Close
Redes sociais sobre Atamyo Therapeutics
- Atamyo Therapeutics na Wikipedia, Google News e Yahoo Finance
- Atamyo Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Stéphane Degove 
Ligue para a Atamyo Therapeutics em +33 404...
